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Introduction
Cogan syndrome (CS) and nail lichen planus represent two autoimmune disorders. Both have been associated with other autoimmune disorders. So far only two cutaneous diseases, none of them lichenoid, were described in patients with CS.
Case Report
We report on a 49-year-old patient that was referred for nail consultation for evaluation of a progressive onychodystrophy involving most of his fingernails. The patient was treated for CS, which had been diagnosed 15 years prior to this consultation, with auditory and ocular involvement. At that time, the therapy included systemic corticosteroids, azathioprine, and cyclophosphamide. Cessation of the acute inflammation was achieved, but the hearing impairment persisted. There was no personal or family history of inflammatory skin diseases or other autoimmune disorders.
Clinical examination revealed thinned nail plates with a rough surface, longitudinal fissuring, and distal onycholysis of eight fingernails. Both the thumb and big toenails showed a thickened nail plate with xanthonychia ( Fig. 1) . Otherwise, examination of the whole body including the hair and mucous membranes was unremarkable. A lateral longitudinal nail biopsy was performed, and light microscopy studies showed a characteristic dense band-like lichenoid lymphocytic infiltrate in the proximal nail matrix and undersurface of the proximal nail fold (Fig. 2) . With this clinicopathological correlation, the diagnosis of nail lichen planus was confirmed.
Discussion CS is a rare type of ANCA-negative vasculitis with predominant involvement of the eyes and vestibulocochlear system. Typical symptoms include keratitis and a Ménière-like triad of vertigo, tinnitus, and sensorineural hearing loss that often persists after remission [1] . Systemic manifestations of vasculitis are present in up to 50% of the patients, with complaints such as fever, arthralgia, and myalgia [1] [2] [3] [4] . Aortitis can evolve as a serious complication of CS [4, 5] . Systemic corticotherapy associated with disease-modifying antirheumatic drugs and TNF inhibitors currently represents the main treatment of CS. Infliximab showed superior effects in vestibuloauditory outcomes in a retrospective study [6] .
In the current literature, pyoderma gangrenosum and vasculitis were described as the only cutaneous manifestations in patients with CS [7] . So far, no lichenoid reactions were reported.
Nail involvement of lichen planus may occur as an isolated finding but more often in association with other mucocutaneous manifestations [8] . Involvement of the nail matrix characteristically leads to thinning of the nail and roughening of the nail surface, called trachyonychia, as well as longitudinal ridging and fissuring. Subungual hyperkeratosis and distal onycholysis as signs of nail bed involvement are less frequent [9] .
Immune dysregulation with a predominantly CD8+ T-cell reaction plays an essential role in the pathophysiology of the disease [10] .
The combination of two or even more autoimmune disorders is not unusual. It is often explained by immunogenetic relations between these diseases. However, until now, no such immunogenetic links between CS and nail lichen planus have been known. Thus, it remains speculative whether this association is just fortuitous or based on a common pathomechanism.
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